Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Inclusion Criteria: * For Dose Escalation Cohort: Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * For Dose Expansion Cohort: HCC patients only: HCC confirmed by biopsy OR diagnosed by clinical and radiologic criteria; all of the following criteria must be met or a biopsy is required: * Known cirrhosis or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection * Hypervascular liver masses \> 2 cm, and either serum alpha-fetoprotein (AFP) \> 400 ng/ml * AFP \> three times normal and doubling in value in the antecedent 3 months * In the expansion cohort, prior treatment with sorafenib as first-line therapy allowed * Any number of the following prior therapies is allowed: * Chemotherapy \>= 28 days prior to registration * Mitomycin C/nitrosoureas \>= 42 days prior to registration * Immunotherapy \>= 28 days prior to registration * Biologic therapy \>= 28 days prior to registration * Targeted therapy \>= 28 days prior to registration * Radiation therapy \>= 28 days prior to registration * Radiation to \< 25% of bone marrow * HCC patients only: Prior regional treatments for liver metastasis are permitted including: * Selective internal radiation therapy such as brachytherapy, cyber knife, radiolabeled microsphere embolization, etc. * Hepatic artery chemoembolization * Hepatic artery embolization * H…